Skip to Content
Merck
  • Extensive SUMO Modification of Repressive Chromatin Factors Distinguishes Pluripotent from Somatic Cells.

Extensive SUMO Modification of Repressive Chromatin Factors Distinguishes Pluripotent from Somatic Cells.

Cell reports (2020-09-17)
Ilan Theurillat, Ivo A Hendriks, Jack-Christophe Cossec, Alexandra Andrieux, Michael L Nielsen, Anne Dejean
ABSTRACT

Post-translational modification by SUMO is a key regulator of cell identity. In mouse embryonic fibroblasts (MEFs), SUMO impedes reprogramming to pluripotency, while in embryonic stem cells (ESCs), it represses the emergence of totipotent-like cells, suggesting that SUMO targets distinct substrates to preserve somatic and pluripotent states. Using MS-based proteomics, we show that the composition of endogenous SUMOylomes differs dramatically between MEFs and ESCs. In MEFs, SUMO2/3 targets proteins associated with canonical SUMO functions, such as splicing, and transcriptional regulators driving somatic enhancer selection. In contrast, in ESCs, SUMO2/3 primarily modifies highly interconnected repressive chromatin complexes, thereby preventing chromatin opening and transitioning to totipotent-like states. We also characterize several SUMO-modified pluripotency factors and show that SUMOylation of Dppa2 and Dppa4 impedes the conversion to 2-cell-embryo-like states. Altogether, we propose that rewiring the repertoire of SUMO target networks is a major driver of cell fate decision during embryonic development.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-ZNF451, affinity isolated antibody
Sigma-Aldrich
Nitrilotriacetic acid disodium salt, Sigma Grade, ≥99%
Millipore
HIS-Select® Nickel Affinity Gel, (1:1 suspension in a 20% ethanol solution)
Sigma-Aldrich
Anti-DPPA-2 Antibody, clone 6C1.2, clone 6C1.2, from mouse